Clinical trials: Ischemia, Brain
Acute Ischemic Stroke
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
Prospective, single-arm, multi-center study to confirm the performance and safety of the iNstroke 6F and 4F thromboaspiration catheter for the treatment of acute ischemic stroke
- Trial name
- iNDUO (NCT07376447)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in France, Germany
- Volunteers
- 160 people
- Sponsor
- iVascular S.L.U.
Acute Ischemic Stroke
Dose Finding Study of MCI-186 in Acute Ischemic Stroke
To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen…
- Trial name
- NCT03346538
- Testing
- Continuous infusion high-dose MCI-186, Continuous infusion low-dose MCI-186, Approved dosing regimen MCI-186
- Where
- 45 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Shionogi
Atrial Fibrillation, Oral Anticoagulation
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO).
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
- Trial name
- INTERCEPT (NCT05723926)
- Testing
- Vine Filter
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Javelin Medical
Acute Ischemic Stroke
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts.
- Trial name
- NCT05547438
- Testing
- NTS-104 TRIS
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroTrauma Sciences, LLC
Ischemic Stroke
A Phase Ib/II in Patients With Acute Ischemic Stroke
Stroke is the fifth leading cause of death in the United States and is the leading cause of long term disability. Distinct geographic disparities in stroke mortality, with highest rates in the southeast United States including…
- Trial name
- NCT02963376
- Testing
- 0.05 mL/kg DDFPe, 0.10 mL/kg DDFPe, 0.17 mL/kg DDFPe
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NuvOx LLC
Stroke
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a…
- Trial name
- REGENESIS (NCT00715364)
- Testing
- NTx™-265: rhCG, then rEPO
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stem Cell Therapeutics Corp.
Stroke
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in acute ischaemic stroke
- Trial name
- VASST (NCT00144014)
- Testing
- V10153
- Where
- 28 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Vernalis (R&D) Ltd
Chronic Ischemic Stroke
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke
- Trial name
- ACTIsSIMA (NCT02448641)
- Testing
- SB623 Implant (2.5M), SB623 Implant (5.0M)
- Where
- 65 sites in United States
- Volunteers
- 163 people
- Sponsor
- SanBio, Inc.
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.
Hypercholesterolemia
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
The purpose of this study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS), in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00082251
- Testing
- Niacin extended release and simvastatin tablets
- Sponsor
- Kos Pharmaceuticals
Stroke, Acute
An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)
RGTA® (ReGeneraTing Agent) are synthetic polysaccharides mimicking extra-cellular matrix scaffold elements and protective agents called Heparan Sulphates (HSPGs). OTR4132-MD is provided as a sterile injectable medical device.
- Trial name
- MATRISS (NCT04083001)
- Testing
- OTR4132MD
- Where
- 3 sites in France
- Volunteers
- 19 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Cardiovascular Event, Parkinson Disease
Cardiovascular Events in Parkinson's Disease Patients
Cardiovascular (CV) disease is a common comorbidity of Parkinson's disease (PD). The background incidence rate of CV events in a levodopa-treated PD population was assessed to better understand these comorbidities in the PD…
- Trial name
- NCT01545856
- Testing
- levodopa
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Severe Hypoxic Ischemic Encephalopathy, Moderate Hypoxic Ischemic Encephalopathy
Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy
The purpose of this study is to assess whether the addition of a drug such as Magnesium sulphate while providing therapeutic hypothermia (or cooling) to babies who are asphyxiated at birth provides additional benefit to the…
- Trial name
- MagCool (NCT01646619)
- Testing
- Magnesium Sulphate
- Where
- 7 sites in Egypt, Malaysia and 4 more
- Volunteers
- 300 people
- Sponsor
- Sajjad Rahman
Stroke, Ischemic
Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke
The ANA catheter system (may also be designated as "ANA system", "ANA 18 -002" or "ANA device") is a distal access catheter designed to assist in neurovascular procedures by facilitating the insertion and guiding of other devices…
- Trial name
- SOLONDA (NCT04095767)
- Testing
- Neurothrombectomy
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Anaconda Biomed S.L.
Hyperlipidemias, Atherosclerosis
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy.
- Conditions
- Hyperlipidemias, Atherosclerosis, Coronary Heart Disease, Carotid Stenosis
- Trial name
- NCT00536965
- Where
- Austria
- Volunteers
- 951 people
- Sponsor
- AstraZeneca
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Safety and Efficacy of CG-BM1 in Ischemic Stroke
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
- Trial name
- NCT07896941
- Testing
- single infusion, 1.0 × 10^6 cells/kg, single infusion, 2.0 × 10^6 cells/kg, single infusion, 3.0 × 10^6 cells/kg
- Where
- China
- Volunteers
- 87 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Ischemic Stroke
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with…
- Trial name
- RHAPSODY-2 (NCT05484154)
- Testing
- 3K3A-APC
- Sponsor
- ZZ Biotech, LLC
Ischemic Stroke
Safety and Performance Evaluation of the Magneto Wire
A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Wire in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.
- Trial name
- NCT03890380
- Testing
- Magneto Wire
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Magneto Thrombectomy Solutions